companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2024
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 7,031,626 and a net result of DKK 1,408,745 compared with DKK 1,086,129 the year before. That is a decrease of 0.5% compared with the year before. Equity amounted to DKK 5,241,109. The solvency ratio was 19.8%. The company had 12 employees in the financial year.
- Gross Profit
- 7,031,626 kr.
- Profit/Loss
- 1,408,745 kr.
- Equity
- 5,241,109 kr.
- Total Assets
- 26,480,501 kr.
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 7 mio. | 1.4 mio. | 5.2 mio. | 12 |
| 2023 | - | 7.1 mio. | 1.1 mio. | 3.8 mio. | 12 |
| 2022 | - | 7.4 mio. | 467 t. | 2.7 mio. | 12 |
| 2021 | - | 4.6 mio. | -631 t. | 2.3 mio. | 10 |
| 2020 | - | 4.5 mio. | -238 t. | 2.9 mio. | 10 |
How creditworthy is Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
As of November 27, 2024, Trine Jakobi Nøttrup has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Charlotte Aaquist Haslund has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Line Bjørge has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Hanna Mikaela Dahlstrand has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Petra Susanne Malander has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Ane Gerda Zahl Eriksson has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 26, 2024, Trine Jakobi Nøttrup has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 26, 2024, Line Bjørge has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2023. Gross profit came to DKK 7,068,563, and the net result was DKK 1,086,129.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.